Status:

COMPLETED

Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers

Lead Sponsor:

Baylor College of Medicine

Collaborating Sponsors:

LifeNet Health

Conditions:

Diabetic Foot Ulcer

Deep Diabetic Foot Ulcer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

Diabetes-related foot ulcers (DFUs) are a leading cause of hospitalization and amputation worldwide, and account for 33% of all direct costs of diabetes care in the US. Ulcers requiring acute care can...

Eligibility Criteria

Inclusion

  • 18 years or older
  • Non-infected deep wounds (Grade 2 Wagner Ulcer Classification)

Exclusion

  • Minors
  • Wounds with bone exposure
  • Active infection
  • Gangrene or osteomyelitis
  • Major vascular problems (ABI \<0.5 or \>1.3)
  • Unable to comply with follow up visits (e.g. long distance travel)
  • Unable or unwilling to provide consent

Key Trial Info

Start Date :

April 2 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 2 2021

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT03476876

Start Date

April 2 2018

End Date

April 2 2021

Last Update

July 7 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Baylor College of Medicine

Houston, Texas, United States, 77030

Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers | DecenTrialz